Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study

BACKGROUND: To assess the efficacy and safety of fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, in metastatic colorectal cancer (mCRC) patients. METHODS: A phase Ib open-label study and phase II randomized, placebo-controlled trial compared the efficacy of fruquintini...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Rui-Hua, Li, Jin, Bai, Yuxian, Xu, Jianming, Liu, Tianshu, Shen, Lin, Wang, Liwei, Pan, Hongming, Cao, Junning, Zhang, Dongsheng, Fan, Songhua, Hua, Ye, Su, Weiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244709/
https://www.ncbi.nlm.nih.gov/pubmed/28103904
http://dx.doi.org/10.1186/s13045-016-0384-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244709/
https://www.ncbi.nlm.nih.gov/pubmed/28103904
http://dx.doi.org/10.1186/s13045-016-0384-9

Ejemplares similares